{"analyses":[{"ciNumSides":"ONE_SIDED","ciPctValue":"85","ciUpperLimit":"1.70","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1419","paramType":"Hazard Ratio (HR)","paramValue":"1.36","statisticalComment":"1-sided statistical test and p-value","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"3.0","value":"2.0"},{"groupId":"OG001","lowerLimit":"1.9","upperLimit":"3.7","value":"2.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"description":"Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and an upper confidence boundary from a 1-sided, 85% confidence interval are estimated using the Kaplan-Meier methods.","dispersionType":"95% Confidence Interval","groups":[{"description":"Protocol therapy will consist of 30 mg MLN0128 (TAK-228) administered weekly over a 4-week cycle.","id":"OG000","title":"Phase II - Analysis Group 2 MLN0128"},{"description":"Patients receive 400mg Pazopanib orally once daily over a 4-week cycle and titrated to tolerance (maximum 800mg) by the treating physician in the first intervention period/initial treatment period.","id":"OG001","title":"Phase II - Analysis Group 2 Pazopanib"}],"paramType":"MEDIAN","populationDescription":"Phase II Analysis Group 2 - Initial Treatment Period","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Progression-free Survival (PFS) (Phase II Analysis Group 2 - Initial Treatment Period)","type":"PRIMARY","unitOfMeasure":"months"}